European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor–Targeted Therapy-Reference-Cited by-同舟云学术

European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor–Targeted Therapy

Published:2016-11 Issue:5 Volume:70 Page:705-706
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Powles Thomas,Staehler Michael,Ljungberg Börje,Bensalah Karim,Canfield Steven E.,Dabestani Saeed,Giles Rachel H.,Hofmann Fabian,Hora Milan,Kuczyk Markus A.,Lam Thomas,Marconi Lorenzo,Merseburger Axel S.,Volpe Alessandro,Bex Axel

Publisher

Elsevier BV

Subject

Urology

Reference5 articles.

1. Cabozantinib versus everolimus in advanced renal-cell carcinoma;Choueiri;N Engl J Med,2015

2. Nivolumab versus everolimus in advanced renal-cell carcinoma;Motzer;N Engl J Med,2015

3. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial;Choueiri;Lancet Oncol,2016

4. Updated EAU guidelines for clear cell renal cancer patients who fail VEGF targeted therapy;Powles;Eur Urol,2016

5. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial;Motzer;Lancet Oncol,2013

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the oncogenic potential of circSOD2 in clear cell renal cell carcinoma: a novel positive feedback loop;Journal of Translational Medicine;2024-06-27

2. Exploring the oncogenic potential of circSOD2 in clear cell renal cell carcinoma: a novel positive feedback loop;2024-03-28

3. Single-cell and spatial transcriptomics reveal 5-methylcytosine RNA methylation regulators immunologically reprograms tumor microenvironment characterizations, immunotherapy response and precision treatment of clear cell renal cell carcinoma;Translational Oncology;2023-09

4. Identification of immune subtypes to guide immunotherapy and targeted therapy in clear cell renal cell carcinoma;Aging;2022-09-01

5. Identifying the role of transient receptor potential channels (TRPs) in kidney renal clear cell carcinoma and their potential therapeutic significances using genomic and transcriptome analyses;BMC Medical Genomics;2022-07-13